Comments on: Trends in 2009: Facing the Challenges of Introducing Biosimilars or Follow-on Biologics in the North American Market

By: Biotech Trends in 2011: Biosimilars « The Cross-Border Biotech Blog

Biotech Trends in 2011: Biosimilars « The Cross-Border Biotech Blog — Wed, 19 Jan 2011 12:29:41 +0000

[...] a Comment Posted by Jeremy Grushcow on January 19, 2011 In our original post on biosimilars, Lumira Capital’s Beni Rovinski set out the business opportunities, the technical challenges an… in 2009. Since then, as Beni predicted, a series of pharma deals have followed Merck’s [...]

By: Biotech Trends Update — Biosimilars Blur IP Constituencies: Novartis and Pfizer-Biocon are Featured in the Economist | The Cross-Border Biotech Blog

Fri, 22 Oct 2010 03:33:16 +0000

[...] which is not expected to hit blockbuster status in its own right. As we have noted before, the high level of expertise required to make biosimilars creates a high barrier to entry and contributes to the field’s attractiveness to traditional [...]

By: EMA Working on Rules for (a few) Antibody Biosimilars « The RIC Blog

EMA Working on Rules for (a few) Antibody Biosimilars « The RIC Blog — Wed, 13 Oct 2010 10:46:33 +0000

[...] I expect these initial inquiries are just the tip of the iceberg. Of couse, biosimilars are hard (as we’ve noted); but a lucrative opportunity of that scale will not go [...]

By: Biotech Trends Update — Biosimilars: FDA Meeting Formally Announced, EMA Working on Rules for (a few) Antibody Biosimilars | The Cross-Border Biotech Blog

Tue, 05 Oct 2010 18:01:55 +0000

[...] I expect these initial inquiries are just the tip of the iceberg. Of couse, biosimilars are hard (as we’ve noted); but a lucrative opportunity of that scale will not go [...]

By: Top 10 Cross-Border Biotech Blog Posts of 2009 « The Cross-Border Biotech Blog

Sun, 03 Jan 2010 22:20:55 +0000

[...] Facing the Challenges of Introducing Biosimilars or Follow-on Biologics in the North American Marke… [...]

By: Top Four Biotech Trends of 2009 « The Cross-Border Biotech Blog

Top Four Biotech Trends of 2009 « The Cross-Border Biotech Blog — Thu, 31 Dec 2009 12:05:25 +0000

[...] but we’re internationalist like that), there’s no denying that biosimilars were a major force in the industry and in politics this year. Some in the press are calling a the 12-year exclusivity period a done [...]

By: GTC Biotherapeutics goes for a Regulatory Double Combo Shot « The Cross-Border Biotech Blog

Fri, 27 Feb 2009 17:35:38 +0000

[...] depends on a continuing trend of GE animal approvals, as well as the successful introduction of a biosimilars pathway in the U.S., as is called for in Obama’s [...]

By: Teva Decides Not to Wait for U.S. Biosimilars Legislation « The Cross-Border Biotech Blog

Fri, 20 Feb 2009 03:53:59 +0000

[...] 19, 2009 · No Comments In Beni’s post earlier this weekon Biosimilars, he identified two major challenges to introducing follow-on biologics into the North [...]